Preview Mode Links will not work in preview mode

Substantial Matters: Life & Science of Parkinson’s

Nov 21, 2017

Alpha-synuclein is a protein in the human brain that is linked with the development of Parkinson’s disease. An important scientific paper came out in September 2017 describing how some common drugs, already approved by the Food and Drug Administration for other purposes, may lower the production of alpha-synuclein...


Nov 7, 2017

Clinical trials – research studies that involve people – are key to medical advances. But sometimes it is hard to recruit and enroll enough participants to make the results meaningful. It is important for people with Parkinson’s disease to participate in clinical trials to help researchers find better ways to...


Oct 24, 2017

Therapies are available to treat Parkinson’s symptoms and improve quality of life for people living with the disease. But we don’t yet have a way to slow or stop Parkinson’s progression, and that is why research is critical. Dr. Tanya Simuni of the Parkinson’s Foundation Center of Excellence at...


Oct 10, 2017

Generic drugs are a cheaper alternative to brand name drugs. But are they as effective? Once the patent on a branded drug expires, other companies are free to apply for approval of a generic version – a drug that acts in the body largely the same as the branded one. Dr. Rajesh Pahwa of the University of Kansas, a...


Sep 26, 2017

When you have a chronic, progressive condition like Parkinson’s disease, there is always something new to learn. But access to information and resources about Parkinson’s varies for individuals and communities. Dr. Claudia Martinez, the Hispanic outreach coordinator at the Muhammad Ali Parkinson Center at the...